Tumor Responses According to Tumor Type in Patients with GEP Tumors and Treated with Various Radiolabeled Somatostatin Analogs
| Center (reference) | Ligand | Tumor response (CR + PR)* | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPT | Carcinoid | Unknown origin | Total | |||||||||
| Functioning | Total | Gastrointestinal | Bronchial | |||||||||
| Basel (5,6) | [90Y-DOTA0, Tyr3]octreotide | NA | 37 (27) | 5 (20) | 20 (10) | 29 (17) | 24 (74) | |||||
| Basel (7) | [90Y-DOTA0, Tyr3]octreotide | NA | 33 (18) | 25 (4) | 0 | 36 (11) | 33 (33) | |||||
| Milan† | [90Y-DOTA0, Tyr3]octreotide | 63 (16) | 51 (45) | 35 (40) | 14 (14) | 21 (14) | 38 (113) | |||||
| Rotterdam (18) | [177Lu-DOTA0, Tyr3]octreotate | 71 (7) | 36 (28) | 20 (35) | 100 (1) | 42 (12) | 30 (76) | |||||